Anzeige
Mehr »
Login
Donnerstag, 25.04.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Wie die Revolution der sauberen Energie eine solide Investitionsmöglichkeit bieten könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
139 Leser
Artikel bewerten:
(0)

RayBiotech, Inc. Convenes 2012 Global Distributor Conference to Address Strategic Growth Objectives

NORCROSS, Ga., Oct. 17, 2012 /PRNewswire/ --RayBiotech, Inc. ("RBI") today announced that it is convening a two-day Global Distributor Conference at its headquarters in suburban Atlanta, Georgia. Distributors representing over thirty-five international countries will participate in this conference where RBI management will address expanded strategic growth objectives for the next five years. In addition, the conference will focus on new product launches, new service offerings and overall technical training related to the RayBiotech portfolio of high-value research products and services. Included will be recognition of those distributors who have excelled in their development of the RayBiotech business within their respective geographic territories. Simultaneous with the Atlanta-based conference, over twenty distributors from throughout China, will be meeting in Chong Qing, China, participating in a similar conference led by Ray Huang, M.D., Ph.D., Co-founder and CEO of RayBiotech, Inc.

Commenting on the Global Distributor Conference, RayBiotech's President, Chief Operating Officer and Co-founder, Ms. Rani Huang, stated, "Significant investments have been made to further enhance our growth and development over the next five years. Particularly, this includes the areas of GLP assay services, Business Development, Sales and Marketing, and especially, our focus on achieving above market-performance through our outstanding distributor network. This is why we're meeting this week, both in Atlanta and in Chong Qing, with our leading distributors to review our growth objectives and plans. We recognize that in order to achieve growth significantly above that of our markets, continuous focus on innovation, high quality products and services and, outstanding execution in customer development, will all be necessary. In addition, we're very pleased to have recently successfully validated the GMP status of the production of our products. We're honored to have such a high-performance Distributor Network and look forward to continued mutual growth and development over the next five years and beyond."

About RayBiotech, Inc.

RayBiotech (http://www.raybiotech.com) pioneered the development of antibody and protein array technologies and provides reliable high-throughput platforms for identifying disease mechanisms, screening and validation of novel biomarkers and identification of new drug targets. In 2001 RayBiotech introduced the first commercially available cytokine antibody array. Since then, RayBiotech array products have been featured in thousands of publications, including some in top-tier journals: Nature, Nature Medicine, Cell, Lancet, PNAS (USA), and many others. Offering more antibody array choices than any of its competitors, RayBiotech has established a leading reputation for the high quality and innovative developments provided to the research community. RayBiotech continues to lead in the development of protein array technologies and is focused on further meeting the needs of clients in translating new knowledge of human biology to improved health. A spin-off from Emory University's School of Medicine, RayBiotech is privately owned, with headquarters in metropolitan Atlanta (Norcross, GA).

For More Information:

Rob Burgess, PhD
Director, Business Development
RayBiotech, Inc.
Phone: 770-729-2992
Email: rob@raybiotech.com

SOURCE RayBiotech, Inc.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2012 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.